In glioblastoma cells the receptor tyrosine kinase c-Met is upregulated in response to bevacizumab and plays an important role in promoting invasion and tumor recurrence. These data support novel links between VEGF-A and hepatocyte growth factor and suggest that c-Met and its signaling effectors may be effective targets for anti-invasive therapies. Clin Cancer Res; 19(7); 1–3. ©2013 AACR.
MET gene expression or pharmacologic inhibition of c-Met kinase activities blocks tumor cell invasion and resistance to bevacizumab. These results are consistent with a 2012 publication by Lu and colleagues, showing that c-Met is upregulated in bevacizumab-treated patient samples and in mosaic mouse models of glioblastoma genetically null for VEGF-A (9). Interestingly, in bevacizumab-sensitive tumors c-Met and VEGFR-2 form heterodimeric complexes that suppress HGF-mediated tumor cell growth and invasion. Met/VEGFR-2 heterodimers associate with the cytoplasmic tyrosine phosphatase PTP1B, which dephosphorylates the c-Met kinase domain and inhibits interactions with proinvasive signaling effectors. Collectively, the data from Aghi and colleagues and Bergers and colleagues (both articles were published collaboratively) reveal cross-talk between the HGF/SF and VEGF-A signaling pathways that negatively regulate tumor cell invasiveness during glioblastoma growth and progression. Met upregulation in response to bevacizumab, probably in combination with other cell-intrinsic and cell-extrinsic events that promote resistance, alters this negative regulation, and drives glioblastoma invasion (Fig. 1).

These data raise several important questions. First, in bevacizumab-resistant glioblastomas, what are the essential pathways that drive VEGF-independent angiogenesis? There are multiple proangiogenic factors; however, one obvious candidate is c-Met, which is expressed in endothelial cells and has proangiogenic functions via HGF/SF (8). Therefore, it is enticing to speculate that in addition to autocrine HGF/c-Met signaling events in invasive tumor cells, HGF/SF may also promote VEGF-independent neoangiogenesis via paracrine signaling between glioblastoma cells and blood vessels. Second, Jahangiri and colleagues have discovered multiple genes that are differentially expressed in glioblastoma samples upon development of bevacizumab resistance. Are these genes differentially expressed in the majority of glioblastoma cells or in select subpopulations of cells? Stem-like glioblastoma cells express VEGF-A and home to perivascular niches (10), suggesting that gene regulation in glioblastoma stem cells may contribute to acquired bevacizumab resistance. Alternatively, glioblastoma cell death may lead to enrichment of subpopulations of intrinsically resistant tumor cells that express high endogenous levels of c-Met. The U87 xenograft selection models suggest gain of resistance as U87 cell lines have been cultured for decades and lack stem-like properties. However, bevacizumab resistance in the U87 models and the primary glioblastoma cultures can be serially passaged, suggesting intrinsic stability. Delineating possible contributions by intrinsically resistant populations of glioblastoma cells in preclinical models and patient samples warrants further investigation. Third, can bevacizumab-resistant tumors be classified on the basis of their molecular genetic characteristics? Bevacizumab-sensitive glioblastoma cells are epithelial-like, whereas resistant cells upregulate some mesenchymal markers. However, the gene expression signatures of resistant tumors are distinct from mesenchymal glioblastomas (11), suggesting that antivascular therapies may generate unique tumor subtypes that should be classified and studied. Fourth, the exact Met-regulated intracellular signaling pathways that drive angiogenic resistance in glioblastomas should be identified.

Figure 1. Roles for c-Met in glioblastoma response and resistance to bevacizumab. A, tumor cell proliferation and invasion are regulated via cross-talk between the VEGF-A and HGF signaling pathways. During glioblastoma growth and progression c-Met and VEGFR-2 form heterodimeric complexes that suppress cell invasion via PTP1B-mediated Met tyrosine dephosphorylation. VEGF-A produced by glioblastoma cells also interacts with its receptors in endothelial cells and promotes angiogenesis and blood vessel permeability. B, bevacizumab neutralizes VEGF-A signaling, leading to endothelial cell death, tumor regression, and transient improvements in progression-free survival. C, responsiveness to bevacizumab is followed by resistance, due to upregulation of c-Met gene expression in glioblastoma cells (acquired resistance) or selective survival of subpopulations of tumor cells that overexpress c-Met (intrinsic resistance). Met forms homodimers that bind HGF/SF and via an autocrine signaling loop induce Stat3 and Fak phosphorylation, promoting a mesenchymal-like phenotype and perivascular tumor cell invasion. In bevacizumab-resistant tumors, paracrine HGF/SF signaling via Met in endothelial cells may also promote VEGF-independent neoangiogenesis.
glioblastoma cell invasion remain to be determined, and identifying these effectors may lead to new therapies. Jahan-giri and colleagues report that Fak and Stat3 signaling effectors are hyperphosphorylated in invasive cells, and there are agents in the clinic that target these proteins. Another related question is whether the major c-Met signaling effector Gab-1 (8) is essential for proinvasive signaling and if Met phosphorylation of Gab-1 is functionally linked to Fak and Stat3. Finally, will combined inhibition of VEGF-A and HGF/SF pathways be effective antiangiogenic and anti-invasive therapies? The dual-specific kinase inhibitor cabozantinib, which targets Met and VEGFR-2, has shown encouraging results in preclinical models of pancreatic cancer (12) and has been approved for medullary thyroid cancers. However, it remains to be determined if clinical trials with this inhibitor or others will effectively impact glioblastoma recurrence and invasion.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Acknowledgments
The author thanks Dr. John de Groot (Department of Neuro-oncology, MD Anderson Cancer Center) for insightful comments on the article.

Grant Support
This study was supported by R01NS059876 and R01NS078402, both from NIH/NINDS.

Received January 28, 2013; accepted February 4, 2013; published OnlineFirst February 12, 2013.

References
Glioblastoma Resistance to Anti-VEGF Therapy: Has the Challenge Been MET?

Joseph H. McCarty

Clin Cancer Res  Published OnlineFirst February 12, 2013.

Updated version  Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-13-0051

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.